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Abstract
Determination of crystal structures of membrane proteins is often limited by difficulties obtaining crystals diffracting to high
resolution. Co-crystallization with Fab fragments of monoclonal antibodies has been reported to improve diffraction of
membrane proteins crystals. However, it is not simple to generate useful monoclonal antibodies for membrane protein
crystallography. In this report, we present an optimized process for efficient screening from immunization to final validation
of monoclonal antibody for membrane protein crystallography.
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Introduction
Since the first high-resolution structure of a membrane protein, the
photosynthetic reaction center, was solved in 1985 [1], more than 290
unique structures of membrane proteins have been reported (database
for membrane proteins of known 3D structure, http://blanco.biomol.
uci.edu/Membrane_Proteins_xtal.html).However, this represents only
a tiny fraction of all membrane protein families. One of the
biggest hurdles in membrane protein crystallography is to obtain
crystals diffracting to high enough resolution for solving the
structure. Crystallization of the membrane protein complexed
with Fab or Fv fragments derived from monoclonal antibodies
has, in a few cases, allowed new structures to be solved for ion
channels, G-protein coupled receptors, and membrane transport-
ers [2,3,4,5,6,7,8].
A crystallographically practicable antibody should meet three
essential criteria. First, the hybridoma cells should secrete
antibodies at a high level (50–100 mg/L culture). Second, the
antibody must make a stable complex with the membrane protein
in detergent solution. Finally, the protein-Fab complex should
crystallize and diffract to ,3A ˚ or better, to enable faithful model
building. Screening of antibodies against discontinuous structural
epitopes is typically performed using the experimental criteria of
positive ELISA (Enzyme-linked immunosorbent assay) on mem-
brane proteins in native conformations but negative western (or
dot-blot) on SDS-denatured proteins [9,10]. However, these
criteria are not foolproof. Since the protein might retain partially
folded structure in the western-blotting environment, so that
discontinuous structural epitopes would score western-positive
[11]. Although monoclonal Fab and Fv fragments have been used
as powerful membrane protein crystallization chaperones, the
procedures for obtaining useful monoclonal antibodies through
conventional methods are time-consuming and costly, either in-
house or by commercial production. Recent developments in
phage and ribosomal display have resulted in faster screening
procedures for antibody fragments and other crystallographic
chaperones [12,13]; however, they both involve proprietary
reagents not yet commercially available.
Here, we describe a ‘‘backyard-factory’’ strategy for screening
antibodies based on our experience in solving the structure of an
Arginine-Agmatine exchange-transporter, AdiC [5], and crystal-
lizing a bacterial CLC channel homologue, CLC-ec2. We have
developed an efficient screening process requiring approximately
three months from immunizing the mice to obtaining antibodies in
sufficient quantity (10–20 mg) for initial crystallization trials
(Fig. 1).
Results and Discussion
Immunization and initial screening
We tested five different preparations of membrane protein
antigens for immunizing mice in order to compare immune
responses to membrane proteins in different environments (in
detergent micelles or reconstituted in liposomes) and different
adjuvants [14,15,16,17]: group 1, membrane protein in detergent
micelles with Freund’s adjuvant; group 2, proteoliposomes with
lipid A (0.1 mg/ml) and aluminum hydroxide (1 mg/ml); group 3,
proteoliposomes with plasmid DNA; group 4, proteoliposomes
diluted in PBS; group 5, proteoliposomes with Freund’s adjuvant.
Although those immunization strategies have not been tested
multiple times on different membrane proteins to make a solid
conclusion, our results on two membrane proteins AdiC and CLC-
ec2 indicate that mice immunized with group 1 and group 2
antigens gave a higher percentage of hybridoma cells secreting
antibodies that bind to natively folded protein (Table 1). After
evaluation of mouse sera by ELISA assay, splenocytes were
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lines. Ten to fourteen days after fusion, clumps of growing cells
appeared in HAT-CM media, and tissue culture supernatants
were screened to identify potentially high-secreting initial
candidates.
Ni-NTA coated 96-well plates were used in ELISA assays for
improved coating of our His-tagged proteins. Tandem dimer AdiC
[5] and half His-tag removed CLC-ec2 were used for coating
ELISA plate to expose as many epitopes as possible on both cis and
trans side in these homodimeric membrane proteins (Fig. 2). In
order to maintain a native state of membrane proteins throughout
the ELISA assay, we included a detergent that was previously
shown with functional reconstitution and chromatographic
behavior to keep the protein properly folded. In the early stages
of screening, it is important to identify hybridoma lines that secrete
high levels of antibodies. Since crystal screens require a large
quantity of the proteins, high yield is a prerequisite for
crystallization trials.
Screening antibodies that selectively bind to structural
epitopes
Initial candidates with high signals (i.e. high secretion) were
further tested in both native and unfolded conditions by ELISA to
sort out antibodies specifically bound to the natively folded
Figure 1. Experimental flowchart and estimated time line of monoclonal antibody screening for membrane protein
crystallography.
doi:10.1371/journal.pone.0024653.g001
Table 1. Statistics of screening antibodies.
AdiC CLC-ec2
Immunization group1 group2 group3 group4 group5 group1 group4
1u ELISA
(Initial positives)
25 33 29 33 25 60 10
2u ELISA
1
(Native&unfolded)
8/18 6/20 3/25 3/33 2/15 29/60 2/10
Subtypes IgG1 0 6
IgG2a 10 7
IgG2b 7 12
IgG3 0 0
IgA 2 1
IgM 3 0
Not determined 0 5
Complex formation
2 22/22 12/31
Legend: The Table reports results of hybridoma production for 7 separate immunizations – 5 with AdiC and 2 with CLC-ec2.
1Displayed are the numbers of clones showing .2-fold brighter ELISA signals in native than unfolded conditions over the number tested.
2Number of antibodies showing a chromatographically satisfactory complex over total tested.
doi:10.1371/journal.pone.0024653.t001
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western-blotting environment [11], protein antigens were dena-
tured in 6 M guanidine-HCl and 0.1 M b-mercaptoethanol,
before coating ELISA plates, and detergent was not used in this
‘‘unfolded ELISA’’ to prevent possible refolding. Previously
validated antibodies against structural epitopes of the KcsA
channel [3] and CLC-ec1 transporter [7] gave negative results
in the ‘‘unfolded ELISA’’ and positive results in the ‘‘native
ELISA’’. These results strongly suggest that membrane proteins
are unfolded under ‘‘unfolded ELISA’’ conditions and remain in
the folded conformation under ‘‘native ELISA’’ conditions (Fig. 3).
We only chose clones showing near background signal in the
‘‘unfolded ELISA’’ and that had a signal in the native ELISA at
least two-fold higher than background. For both of our test
proteins, about 30% of antibodies were selected as specific against
the native conformation (Table 1 and Fig. 2). These initial
candidates were further scrutinized to select final cell lines.
Although at this stage the cells are not yet cloned, our experience
has shown that it saves significant time to assess antibody secretion
and complex formation before establishing the hybridoma line.
Purification strategy for different classes of
immunoglobulin
Immortalized hybridoma cells secrete several distinct classes of
immunoglobulin such as IgA, IgG and IgM molecules. In order to
optimize the purification methods for each of these, we subtyped
the initial candidates. Of 53 initial candidates, 3 were IgM, 3 were
IgA and 42 were IgG (Table 1). Although it is possible that each
uncloned initial candidate might contain more than one specific
hybridoma, our results showed that such cases rarely occurred.
After subtyping, we grew the initial candidates and purified
antibodies from the supernatants using different chromatographic
methods according to subtype. Initially, cells were grown for two
weeks in 15-cm plates, each producing 200 mL of supernatant. All
IgG subclasses (IgG1, IgG2a, IgG2b, and IgG3) were purified
using protein G affinity columns. Since the Fc regions of IgA and
IgM are hidden due to their multivalent structures, protein G
columns cannot purify them. Instead, protein L affinity columns
were used for IgA and IgM with kappa light chains, and
hydroxyapatite for those with lambda light chains. Typically, a
single plate yielded 5–20 mg of purified antibody.
Evaluation of purified antibody
The ability of antibodies to form stable complexes was tested
next. One major difficulty in membrane protein crystallization is
due to the flexibility of its conformation, especially in the loops
outside of the transmembrane region. These loops greatly affect
the crystal packing. Fab acts as a chaperone stabilizing a certain
conformation of the membrane protein, and also increases the
polar surface of protein to facilitate packing [9]. Therefore, only
tightly bound Fabs are suitable since weakly bound Fabs would
increase heterogeneity of the crystallization mixture. For multi-
transmembrane proteins, Fabs bound to several epitopes in
different loops (discontinuous structural epitopes) can increase
the structural stability of the protein tremendously leading high
quality crystals.
A mixture of antibody and membrane protein in detergent
micelles was run on a 24-mL Superdex 200 size-exclusion column.
A useful protein-antibody complex elutes around 9–10 ml volume,
Figure 2. Schematic illustration of His-tagged membrane
proteins on Ni
2+-coated plate. Since AdiC and CLC-ec2 form stable
dimers, a single His-tag system could be better to expose both cis- and
trans-sides to the solution (right) than doubly tagged dimer (left).
doi:10.1371/journal.pone.0024653.g002
Figure 3. Representative ELISA results for the 12 initial candidates (a-l) for CLC-ec2 in the native or unfolded condition. Ctrl1 and
Ctrl2 represent controls for test-bled serum (1/1000 dilution) on CLC-ec2 and anti-CLC-ec1 antibody (1 mg/mL concentration) on CLC-ec1,
respectively. The dashed line indicates the cut-off line for negative result in the unfolded condition. Clones showing a negative signal in unfolded
condition and that had a signal at least twice higher than background in the native conditions were to be tested further (marked as *).
doi:10.1371/journal.pone.0024653.g003
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eluting at ,12.5 ml (Fig. 4A and B). Stable antibody-protein
complexes formed from all AdiC antibodies, but only less than half
of CLC-ec2 antibodies (Table 1).
Preparation of Fab-membrane protein complex and
crystallization trial
In the final round of screening, Fab fragments are evaluated. We
developed a quick procedure to test membrane protein-Fab
complex formation without purifying the Fab fragment. First, it is
necessary to assess the sensitivity of the membrane proteinto papain
cleavage. CLC-ec2 is not cleaved by papain, so antibodies for this
protein were digested with soluble papain to produce a mixture of
Fab/Fc fragments. However, AdiC is very susceptible to papain in
trace amounts; we thereforeused immobilized papainfor producing
Fab fragments in this case. After 2–6 hours of papain treatment, an
excess of the Fab/Fc mix was combined with membrane protein
and loadedonto a Superdex200column.The pure Fab/membrane
protein complex elutes well ahead of both the membrane protein
alone and the Fc fragment (Fig. 4C and D). The complex was
concentrated to ,10 mg/mL for crystallization trials. After initial
crystallization trials, the promising candidates were established as
stable monoclonals by limiting dilution. These lines were grown in
2 L gas permeable bottles to obtain .100-mg quantity of antibody
for further optimization of diffraction quality.
Our experience in solving a AdiC-Fab complex structure has
shown that among 22 antibodies that form complexes with AdiC
and crystallize to diffracting crystals, 3 Fabs improved the
resolution from anisotropic 4–7 A ˚ to isotropic 3 A ˚ resolution
(Fig. 5). The structure was solved with Fab21-AdiC complex
crystals [5].
Concluding remarks
Structures of many membrane proteins have been solved without
crystallographic chaperones; however, in cases of certain intractable
membraneproteins,Fabfragmentchaperonescanlead tosuccessful
structure determination [4,5,6,8]. Our experiences on a few
membrane proteins have indicated that Fab is especially helpful
for the proteins that can already form low resolution diffracting
crystals. Comparing with many other techniques for membrane
protein crystallization optimization such as ‘‘random’’ mutagenesis,
homologue screen, detergent screen and mixture and so on,
generating Fab is a ‘‘rational’’ approach, but used to be considered
very time-consuming and costly. With our high-efficiency screening
reported here, generating Fab for membrane protein crystallization
has become quite manageable in a regular research lab.
Figure 4. Evaluation of membrane protein-antibody complexes. A. Size-exclusion chromatography profiles of protein-antibody complexes.
CLC-ec2 alone eluted at ,12 mL (black line). Chromatogram of clone #6 showed two peaks at ,9 mL for antibody-CLC-ec2 complex and at ,13 mL
for free antibody (light gray line). However, clone #16 eluted at ,12.5 mL as a single broad peak (gray line), which represents co-migration of
unbound antibody and CLC-ec2. B. Early peak fractions around 9–11 mL from size-exclusion column were run on SDS-PAGE. C. Fab#6-CLC-ec2
complex (light gray line) is eluted ,0.5 mL earlier than CLC-ec2 alone (black line) followed by free-Fab and Fc in 15–16 mL position. D. Fab-CLC-ec2
complex fractions were resolved by SDS-PAGE.
doi:10.1371/journal.pone.0024653.g004
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Ethics statement
This study was performed in strict accordance with the Guide
for the Care and Use of Laboratory Animals of the National
Institutes of Health. The protocol was approved by the
Institutional Animal Care and Use Committee of Brandeis
University (Permit Number: 0809-43).
Immunization and fusion
The standard immunization procedure was followed as
described [17]. In short, 8-week-old BALB/c female mice were
injected with 50 mg of antigen in 200 ml into the peritoneal cavity
(intraperitoneal injections, ip). Two weeks after the first injection,
mice were boosted with a second ip injection. A week later, mice
were test-bled and the immunizations were evaluated using ELISA
assay. Mice showing a robust immune response were further
injected with both 2–5 mg of antigen into the tail vein (intravenous,
iv) and 50 mg into the peritoneal cavity.
The mice were injected with the following five groups of
different adjuvant conjugated antigens: group 1, membrane
protein in detergent mixed with Freund’s adjuvant (antigen:adju-
vant is 1:1 (v/v)); group 2, proteoliposomes (membrane protein
reconstituted into the lipid vesicles at the ratio of 100 mg/mg lipid
in PBS buffer) mixed with lipid A (0.1 mg/ml) and aluminum
hydroxide (1 mg/ml); group 3, proteoliposomes mixed with
plasmid DNA (liposome:DNA is 1:1 (v/v), plasmid DNA
concentration is 0.5 mg/ml); group 4, proteoliposomes diluted in
PBS buffer without adjuvant (liposome:PBS is 1:1 (v/v)); group 5,
proteoliposomes mixed with Freund’s adjuvant (liposome:adjuvant
is 1:1 (v/v)). Complete Freund adjuvant (CFA) for the first ip
injection, and incomplete Freund adjuvant (IFA) for the following
boost injections were used. In each group, two mice with the
highest ELISA signal were given a third injection (both ip and iv).
Note that for the groups with Freund as adjuvant, iv injections
should not include Freud since it is very toxic and may kill the
mice.
Two mice showing high ELISA signals from sera were sacrificed
and spleens were isolated. Splenocytes were fused with the
immortalized myeloma cell line Sp2/0-Ag14 (CRL-1581, ATCC)
as previously described [17]. Briefly, splenocytes were mixed with
Sp2/0 cell (3:1 ratio), cells were spun, and 1 mL of 50% PEG1500
(w/v, Roche) was added to cell pellet drop-by-drop over 1 min.
Then complete media (CM; 10% NCTC media (v/v), 2 mM
glutamine, 1 mM sodium pyruvate, 1% MEM NEAA (v/v),
50 mg/mL gentamycin in DMEM (high glucose, Gibco)) was
added to cells following sequences: 1 mL after 1 min, 2 mL after
2 min, 4 mL after 4 min and the final volume was brought to
15 mL. After spinning, the cells were resuspended in FBS and sat
for 15 min. HAT-CM (CM with 10% hybridoma cloning factor
(Roche) and 16 HAT supplement (Gibco)) was added to make
final 20% FBS and cells were plated in 96 well plate at a density of
2610
4 Sp2/0 cells per well.
ELISA and antibody subtyping
In order to evaluate hybridoma supernatants, ELISA assays
were performed in native or unfolded conditions. His-tagged
tandem dimer AdiC was expressed and purified as described [5].
CLC-ec2 was cloned in pASK90 vector with C-terminal His-tag,
expressed in E.coli BL21 (DE3), and purified on Co-affinity column
(BD Biosciences). The His-tag was completely removed by a 1-hr
digestion with lysine endoproteinase C (LysC, 0.02 U/mg protein;
Roche). For obtaining half His-tag removed CLC-ec2, proteolysis
was performed for 0.5 hr with 1/10 of LysC (0.002 U/mg
protein). Half His-tag removed CLC-ec2 was further purified on
the size-exclusion chromatography and evaluated in SDS-PAGE.
For ELISA under native conditions, His-tagged tandem dimer
AdiC or half His-tag removed CLC-ec2 were diluted in PBS-
DDM-BSA (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM
Na2HPO4, 1.76 mM KH2PO4, pH 7.4, and 2 mM dodecyl-b-
D-maltopyranoside (DDM, Anatrace) and 2 mg/mL BSA) at
20 mg/mL and 50 mL of protein (20 mg/mL) was incubated in
each well of Ni-NTA HisSorb 96-well plates (Qiagen) for 1 hr at
room temperature. After washing 3 times with PBS-DDM (16
PBS with 1 mM DDM), 50 mL of tissue culture supernatant and
50 mL of PBS-DDM-BSA were added to each well and incubated
for 1 hr. Subsequently, wells were washed and incubated with a 1/
2000 dilution of rabbit anti-mouse IgG antibodies (Promega) in
PBS-DDM-BSA for 45 min. After washing 2 times with p-
nitrophenyl phosphate (PNPP) reaction buffer followed by 3
washes with PBS-DDM, color development was initiated with
100 mL of PNPP (1 mg/mL). The reaction was stopped by
addition of 50 mL of 2 M NaOH and the signal was read at
405 nm on a plate reader (Molecular Device). For unfolded
conditions, membrane proteins (120 mg/mL) were treated with
6 M guanidine-HCl and 0.1 M b-mercaptoethanol at 90uC for
10 min, diluted six-fold with PBS and coated in Ni-NTA HisSorb
plate. ELISA procedures were the same as native conditions
Figure 5. Improving diffraction patterns with one of the advantageous antibodies. A. Typical diffraction pattern of AdiC crystal. B.
Diffraction pattern of AdiC-Fab21 complex.
doi:10.1371/journal.pone.0024653.g005
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Mouse Typer Sub-isotyping kit (Bio-Rad). Manufacturer’s instruc-
tions were followed, except that using Ni-NTA coated plates were
used and detergent was included in each step.
Clonal selection
Monoclonal cell lines were established by limiting dilution [17].
Briefly, cells were diluted in CM-HAT with 20% FBS and 10%
hybridoma cloning factor (Roche) at 0.25–1 cell per well and
plated on 96-well plate. Supernatants were screened by ELISA
after 10-day cultivation. Cells were subsequently transferred to 12-
well, 6-well and 10-cm plates. After growing to confluence, FBS
was lowered from 20% to 5% in 5% steps. For large scale
production of monoclonal antibody, the monoclonal cells adapted
in CM with 5% FBS were grown in two 15 cm-plate for 3–5 days,
transferred in 2 L gas permeable culture bottles (Wilson Wolf
Manufacturing). Two to four weeks after growing, antibodies were
purified as described.
Affinity purification of antibodies
Affinity purification on Protein G beads was used for IgG and
on Protein L beads for IgM and IgA subclasses containing kappa
light chains. Affinity resin (1 mL bed for 100 mL culture,
Genscript) was packed in glass columns and the filtered tissue
culture supernatant was loaded at 2–4 mL/min while optical
density (OD) was monitored at 280 nm. The column was washed
with PBS to baseline OD, and antibodies were eluted with 0.1 M
glycine (pH 2.7). The eluate was immediately neutralized by
addition of 0.2 volumes of 1 M tris-HCl, pH 8.0.
For IgM and IgA containing lambda light chain, hydroxyapatite
columns were used. One gram of ceramic hydroxyapatite (Bio-
Rad) was activated with 10 mL of 200 mM Na-phosphate, pH 8.0
and equilibrated in 10 mM Na2HPO4, pH 6.5. Before loading,
Na2HPO4 was added to the tissue culture supernatant at final
5 mM and pH was adjusted to 6.5. After loading the sample and
washing with equilibration buffer, proteins were eluted with two
sequential linear gradients (40 column volumes each): equilibra-
tion buffer/high-salt buffer (2 M NaCl, 10 mM Na2HPO4,
pH 6.5) and equilibration buffer/cleaning buffer (500 mM
Na2HPO4, pH 6.5). The various antibodies eluted at different
positions in these gradients.
Papain digestion
Either immobilized (Pierce) or soluble (Roche) papain was
mixed with purified antibody (5 mg/mL) at a 0.5–2% weight ratio
in cutting buffer (20 mM Na2HPO4, 10 mM EDTA, 20 mM
cysteine, pH 7.0) and incubated at 37uC. To follow proteolysis
kinetics for each antibody, 50 mg of the digestion reaction was
stopped at the desired time (0.5–6 hr) either by addition of 25 mM
iodoacetamide (for soluble papain) or removing immobilized
papain by filtering. For typical preparative-scale (10–100 mg) Fab
production, purified antibody (5 mg/mL) was incubated in cutting
buffer with papain (10 mg/mg of antibody) at 37uC for 1–3 hr. It
was necessary, however, to pre-determine cutting conditions for
each antibody by analytical-scale test reactions. The digestion
mixture of Fab and Fc is directly used for complex formation after
dialyzing excess iodoacetamide and cysteine out.
Complex formation and size-exclusion chromatography
For screening of complex formation, purified AdiC or CLC-ec2
(0.2–0.5 mg) was incubated for 1 hr at room temperature with
purified full length antibody, purified Fab, or Fab/Fc mixture (3-
fold excess for antibody and Fab/Fc mixture or 1.5-fold for
purified Fab by OD280) in the presence of detergent. The mixture
was loaded on a 24-mL bed volume Superdex 200 size-exclusion
column (GE healthcare) equilibrated in 100 mM NaCl, 10–
20 mM tris-HCl, pH 7.5 with 5 mM DM or 2 mM DDM. Fab-
complexes eluted at 11–12 mL elution fraction, with free Fab and
Fc eluting around 15–16 mL. Eluted complexes were concentrat-
ed to 10 mg/mL and used for crystallization.
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